The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Straver, Marieke E.; Glas, Annuska M.; Hannemann, Juliane; Wesseling, Jelle; Vijver, Marc J. van de; Rutgers, Emiel J.; Peeters, Marie‐Jeanne T. F. D. Vrancken; Tinteren, Harm van; Veer, Laura J. van’t; Rodenhuis, S.

doi:10.1007/s10549-009-0333-1

Cited by 225 publications

(127 citation statements)

References 28 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…8,13,[22][23][24][25] Evidence supporting the predictive value of the 70-GS on CT benefit is limited; therefore, its clinical utility mainly lies in its prognostic capacity. [26][27][28] Currently, the MINDACT trial is being conducted and the first results are expected by the end of this calendar year, which will further assess the predictive capacity of the 70-GS in a randomized prospective setting. 9 In the present study, i.e., in patients who were treated within the indicated area for gene expression profiles characterized as having a fairly good prognosis, it was the prognostic value of the 70-GS that was used to discern a group of patients with such good outcome that no substantial benefit was to be expected of adjuvant CT.…”

Section: Discussionmentioning

confidence: 99%

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Kuijer

Bommel

Drukker

et al. 2016

Genetics in Medicine

View full text Add to dashboard Cite

Methods:Patients within a national guideline directed indication area for 70-GS use who were surgically treated between November 2011 and April 2013 were selected from the Netherlands Cancer Registry database. The effect of 70-GS use on the administration of CT was evaluated in guideline-and age-delineated subgroups addressing potential effect of bias by linear mixed-effect modeling and instrumental variable (IV) analyses.Results: A total of 2,043 patients within the indicated area for 70-GS use were included, of whom 298 received a 70-GS. Without use of the 70-GS, 45% of patients received CT. The 70-GS use was associated with a 9.5% decrease in CT administration (95% confidence interval (CI): −15.7 to −3.3%) in linear mixed-effect model analyses and IV analyses showed similar results (−9.9%; 95% CI: −19.3 to −0.4). Conclusion:In patients in whom the Dutch national guidelines suggest the use of a gene-expression profile, 70-GS use is associated with a 10% decrease in the administration of adjuvant CT. Genet Med advance online publication 19 November 2015

show abstract

Section: Discussionmentioning

confidence: 99%

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Kuijer

Bommel

Drukker

et al. 2016

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

“…Some practitioners may believe that because overall survival is the same whether chemotherapy is given preoperatively or in the adjuvant setting, the only clinical indication for PC is to give a patient with a large cancer the possibility of conserving her breast. In modern breast cancer treatment, with better technology allowing physicians to determine more accurately which patients benefit from chemotherapy, PC can be applied to a more appropriate and carefully selected patient population [13][14][15][16][17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Preoperative Chemotherapy for Operable Breast Cancer Improves Surgical Outcomes in the Community Hospital Setting

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Similarly, the pCR rate was higher in triple-negative tumors (28) and in ductular than in lobular cancer (29). Several molecular signatures are being tested in the neoadjuvant setting (30)(31)(32)(33). However, the benefit of using genetic predictors over usual pathological biomarkers is not clear.…”

Section: Discussionmentioning

confidence: 99%

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

et al. 2012

View full text Add to dashboard Cite

Abstract.A pathological complete response (pCR) after neoadjuvant chemotherapy is observed in approximately 20% of breast cancer patients. A proteomic analysis was performed on plasma and tumor tissue before treatment to evaluate its potential impact on the prediction of response. One hundred and forty-nine breast cancer patients eligible for neoadjuvant chemotherapy were included in the study between February 2004 and January 2009 at three centers. The proteomic analysis was performed using SELDI Technology (ProteinChip CM10 pH4, IMAC-Cu and H50). Three acquisition protocols were used according to the mass range. Plasma and tumor proteomic signatures were generated using generalized ROC criteria and cross-validation. Twenty-eight (18.8%) patients out of 149 experienced a pCR according to Sataloff criteria. In the cytosol analysis, respectively 4, 2 and 8 proteins had significantly different levels of expression in the responders and non-responders using IMAC-Cu, H50 and CM10 pH4. Among the 8 proteins of interest on CM10 pH4, 2 (C1 and C7) were selected and were validated in 95.0 and 85.6% of the models. In the plasma analysis, respectively 12, 6 and 2 proteins had different levels of expression using the same ProteinChips. Among the 12 plasma proteins of interest on IMAC-Cu, 2 (P1 and P7) were selected and were validated in 94.8 and 97.6% of the models. A combined proteomic signature was generated, which remained statistically significant when adjusted for hormone receptor status and Ki-67. Our results show that proteomic analysis can differentiate complete pathological responders in breast cancer patients after neoadjuvant chemotherapy.

show abstract

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Cited by 225 publications

References 28 publications

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Preoperative Chemotherapy for Operable Breast Cancer Improves Surgical Outcomes in the Community Hospital Setting

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

Contact Info

Product

Resources

About